Exiqon operates in two business areas, Life Sciences and Diagnostics, which share:

• One vision - pursue new scientific discoveries to improve healthcare
• One focus - the promise of miRNA as biological markers
• One technology platform - our proprietary LNA™ (Locked Nucleic Acid) detection technology.

Exiqon’s Life Sciences business and its diagnostics pipeline are helping drive the development towards new diagnostic capabilities and personalized medicine by helping scientists understand the biological function of miRNAs.

Exiqon Life Sciences is a leading one-stop supplier of products for miRNA research. Researchers around the world in academia, the biotechnology industry and recently the pharmaceutical industry, are using our research products to help better understand the biology of miRNAs which will contribute to making personalized medicine a reality.

Exiqon Diagnostics has a portfolio of new diagnostic and prognostic products in development that are based on miRNA as a biological marker. These products can help physicians treating cancer make the most appropriate treatment decisions. By allowing early detection of cancer or relevant stratification of patient populations, our diagnostic products aim to make it possible to increase the success rate of therapies and reduce the risk of adverse side effects and unnecessary costs.

Exiqon has is listed on the NASDAQ OMX in Copenhagen.